Advertisement

Topics

Genethon and AFM (French Muscular Dystrophy Association) Company Profile

01:16 EDT 21st September 2017 | BioPortfolio


News Articles [1564 Associated News Articles listed on BioPortfolio]

Sarepta, Genethon to research muscular dystrophy treatment

Sarepta Therapeutics and Genethon have agreed to conduct joint gene-therapy research into Duchenne muscular dystrophy, combin -More- 

Microdystrophin restores muscle strength in Duchenne muscular dystrophy

Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR) and the Royal Holloway University of London demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne mu...

Sarepta, Genethon collaborate for Duchenne muscular dystrophy

Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular disea...

Gene therapy: Microdystrophin restores muscle strength in Duchenne muscular dystrophy

(AFM-Téléthon) Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy...

Preclinical study demonstrates efficacy of gene therapy in treatment of Duchenne muscular dystrophy

Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment...

Sarepta And Genethon Announce A Gene Therapy Research Collaboration For The Treatment Of Duchenne Muscular Dystrophy

  Life Sciences Jobs   ...

Shortened telomeres linked to dysfunction in Duchenne muscular dystrophy, researchers find

A discovery about muscular dystrophy disorders has been made that suggests new possibilities for treatment. Researchers found that stem cells in the muscles of muscular dystrophy patients may, at an e...

Sarepta Therapeutics and Genethon announce gene therapy research collaboration for Duchenne muscula

(AFM-Téléthon) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), and Genethon have signed a gene therapy research collaboration to jointly develop treatments for Duchenne muscular dystrophy (DMD).

PubMed Articles [3153 Associated PubMed Articles listed on BioPortfolio]

Parents' Reactions to the Diagnosis of Duchenne Muscular Dystrophy: Associations Between Resolution, Family Functioning, and Child Behavior Problems.

Duchenne muscular dystrophy (DMD) is the most frequent inherited form of muscular dystrophy during childhood. DMD is a severe and progressive disease. Children initially have no symptoms, but the diag...

Upper limb functional assessment scale for children with Duchenne muscular dystrophy and Spinal muscular atrophy.

Duchenne muscular dystrophy (DMD) and Spinal muscular atrophy (SMA) causes significant disability and progressive functional impairment. Readily available instruments that assess functionality, especi...

Longitudinal Community Walking Activity in Duchenne Muscular Dystrophy.

Natural history studies for Duchenne muscular dystrophy (DMD) have not included measures of community ambulation.

Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is a severe muscular disease characterized by progressive loss of functional muscle mass followed by changes in body composition.

Translation and validation of the Life Satisfaction Index for Adolescents scale with neuromuscular disorders: LSI-A Brazil.

To validate the Life Satisfaction Index for Adolescents (LSI-A) scale, parent version and patient version, for Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA) and limb-girdle muscular...

Clinical Trials [2073 Associated Clinical Trials listed on BioPortfolio]

Ramipril Versus Carvedilol in Duchenne and Becker Patients

Data on preventive therapy in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) affected individuals without cardiac involvement are very limited and currently lacking ...

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

The purpose of this study is to determine if ACE-031 is safe and well-tolerated in children with Duchenne Muscular Dystrophy (DMD) and to select the optimal doses of ACE-031 in terms of sa...

A Study of TAS-205 for Duchenne Muscular Dystrophy

The objective of this study is to evaluate the efficacy after 24-week repeated oral doses of TAS-205 in patients with Duchenne Muscular Dystrophy (DMD) in an exploratory manner.

Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy

This study will help to determine the effectiveness of glutamine and creatine as a possible therapy for DMD. Boys with DMD who are enrolled in this trial will be randomly chosen to receiv...

Cardiac Outcome Measures in Children With Muscular Dystrophy

The purpose of the research study is to evaluate different cardiac measures that are obtained by echocardiographic tests in patients with muscular dystrophy.

More Information about "Genethon and AFM (French Muscular Dystrophy Association)" on BioPortfolio

We have published hundreds of Genethon and AFM (French Muscular Dystrophy Association) news stories on BioPortfolio along with dozens of Genethon and AFM (French Muscular Dystrophy Association) Clinical Trials and PubMed Articles about Genethon and AFM (French Muscular Dystrophy Association) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genethon and AFM (French Muscular Dystrophy Association) Companies in our database. You can also find out about relevant Genethon and AFM (French Muscular Dystrophy Association) Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record